Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Takecab

- PMLiVE

AbbVie wins key approval for hep C pill Viekira Pak

Prices all-oral treatment fractionally lower than rivals from Gilead

- PMLiVE

NICE backs three ulcerative colitis treatments

Remicade, Simponi and Humira recommended for NHS reimbursement

- PMLiVE

Novartis’ Cosentyx beats Stelara in psoriasis study

Cosentyx achieved clearance in 70% of patients

National Institute for Health and Care Excellence NICE logo

Janssen sways NICE with Stelara discount

UK health watchdog set to recommend drug in psoriatic arthritis after agreeing patient access scheme

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

EMA recommends two AbbVie treatments for hepatitis C

Exviera and Viekirax backed for use in Europe

EU flag

EU watchdog raps EMA for redacted AbbVie data

Issues over the redaction of clinical study reports

- PMLiVE

AbbVie takes home company of the year at PMEA 2014

Firm is rewarded for its patient-focus

- PMLiVE

Amgen and AZ’s psoriasis antibody beats Stelara in study

Brodalumab cleared all skin lesions in 37% compared to Stelara’s 18.5%

- PMLiVE

Takeda enlists GE’s aid to tackle liver fibrosis epidemic

Non-alcoholic liver disease has doubled in the last 20 years

- PMLiVE

FDA approves Olysio/Sovaldi combination in hep C

Janssen drug recommended for use along with Gilead’s blockbuster

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links